CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

83 papers

Active filtersClassification:Supporting

Showing 37-48 of total 83 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

In vivo genome-wide CRISPR screens identify FOXR1 as a suppressor of CD8(+) T cell antitumor immunity.

Yang X; Ouyang H; Xu H; Peng L; Cui J; Zhang B; Huang B; Wang C; Li G; Cao X

2026PubMedSupporting evidence

Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.

Dumbrava EE; Oh DY; Ryu MH; Calvo E; Garralda E; Chung WP; Bai LY; Rojas K; Yildirim O; Masciari S; Mi G; Wang L; Rotolo F; Gailhac S; Attieh E; Kanlikilicer P; Buday B; Perez R; Rharbaoui F; Abbadessa G; Moreno V

Jan 1, 2026Journal for immunotherapy of cancer

2026PubMedSupporting evidence

[Advances in single cell omics applications in mantle cell lymphoma].

Wang C; Zhang Q; Cao X

Jan 1, 2026Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

2026PubMedSupporting evidence

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

Panozzo B; Robinson S; Minson AG; Li J; Baldwin K; Scott HW; Oliaro J; Wong AJN; van der Linde S; O'Leary NL; Thompson PA; Seymour JF; Anderson MA; Tam CS; Harrison SJ; Dickinson MJ; Westerman DA; Dowling MR

Jan 1, 2026British journal of haematology

2026PubMedSupporting evidence

Rational Engineering of Notch1 Signaling to Boost the Proliferation of CD19-BBζ CAR-T.

Phillips MK; Birocchi F; Korell F; Salas-Benito D; Blumenberg V; Escobar G; Bouffard AA; Elsallab M; Fan Y; Takei HN; Armstrong A; Supper VM; Gallagher KM; Bailey SR; Berger TR; Leick MB; Mucci A; Maus MV

Jan 1, 2026Blood

2026PubMedSupporting evidence

Parallel processing of T cells and natural killer cells to enhance in vivoCAR T cell activity against blood and solid cancers.

Dobson LJ; Marron PW; Drabble AH; Liyanage TD; Pe KC; Slaney CY; Hock BD; McLellan AD

Jan 1, 2026Clinical & translational immunology

2026PubMedSupporting evidence

Integrated Immunotherapy Target Atlas for Ewing Sarcoma.

Goldman C

Jan 1, 2026Cancer genomics & proteomics

2026PubMedSupporting evidence

Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens.

Hofmann M; Unverdorben F; Pszolla MG; Aschmoneit N; Hutt M; Manz T; Schuster H; Hukelmann J; Acs A; Tenkerian C; Missel S; Mølhøj M; Schräder C; Wagner C; Maurer D; Bunk S; Reinhardt C

Jan 1, 2026mAbs

2026PubMedSupporting evidence

GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.

Pan D; Kumar A; Lipof JJ; Chung A; Wolf JL; Martin TG 3rd; Arora S; Sayre PH; Chari A

Jan 1, 2026Cancer

2026PubMedSupporting evidence

Isolating T-Cell Potent Lentiviral Vector Subpopulations through Rational Design of Nanofiber Anion-Exchange Adsorbents.

Pamenter G; Ovari G; Kulkarni A; Williams-Fegredo T; Knevelman C; Mitrophanous K; Davies L; Foroutan F; Townsend M; Goldrick S; Bracewell DG

Jan 1, 2026Biotechnology and bioengineering

2026PubMedSupporting evidence

[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].

Kawamoto H; Kawase T; Nagano S

Jan 1, 2026[Rinsho ketsueki] The Japanese journal of clinical hematology

2026PubMedSupporting evidence

Scalable Production of Transfection-Grade Plasmid DNA by Liquid-Liquid Extraction Without Chromatography: Application to CAR-T Vector Packaging.

Nigmatulla G; Kydyrbayeva A; Kulatay T; Zauatbayeva G; Ingirbay B; Sagyndykova L; Keyer V; Zharlyganova D; Zhumabekova M; Shustov AV

Jan 1, 2026Bioengineering (Basel, Switzerland)